While Novartis stops distribution of the hismaine-2 blocker ranitidine because of presence of N-nitrosodimethylamine (NDMA), a probable carcinogen, Sanofi plans to continue distributing Zantac OTC in the US. Novartis AG, licenses OTC Zantac formulations for US marketing to Sanofi. A representative for Sanofi’s US consumer health products division has said NDMA levels in ranitidine “barley exceed amounts found in common foods” and that they are working closely with the FDA and conducting our own investigations. This HBW story looks at the details around ranitidine and NDMA and actions being taken around the world based on each country’s regulatory bodies.